Abcuro Raises $66 Million to Fund Second Registrational Attempt in Inclusion-Body Myositis
Abcuro closed a $66 million Series D financing to fund a new, potentially registrational study of ulviprubart in people with less severe inclusion-body myositis (IBM). New Leaf Venture Partners led the round, with Rock…
